Drug Trial Radar · NCT05382559
A Study of ASP3082 in Adults With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
681
Planned (sponsor's estimate)
Start
Jun 8, 2022
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the results from this group and decide if the next group can receive a higher dose of ASP3082. The panel will do this for each group until all groups have received ASP3082 (by itself or together with cetuximab) or until suitable doses have been selected for Part 2. In Part 2, ASP3082 will be given in by itself, or in combination with the other study treatments. Study treatments will be given through a vein. This is called an infusion. Each treatment cycle is 21 or 28 days long. They will continue treatment until: they have medical problems from the treatment they can't tolerate; their cancer gets worse; they start other cancer treatment; or they ask to stop treatment.
Conditions
- Solid Tumor
Interventions
SetidegrasibDrug
Intravenous Infusion
CetuximabDrug
Intravenous Infusion
LeucovorinDrug
Intravenous Infusion
OxaliplatinDrug
Intravenous Infusion
FluorouracilDrug
Intravenous Infusion
IrinotecanDrug
Intravenous Infusion
Nanoparticle albumin-bound-paclitaxelDrug
Intravenous Infusion
GemcitabineDrug
Intravenous Infusion
DocetaxelDrug
Intravenous Infusion
PembrolizumabDrug
Intravenous Infusion
CisplatinDrug
Intravenous Infusion
CarboplatinDrug
Intravenous Infusion
PemetrexedDrug
Intravenous Infusion
Liposomal IrinotecanDrug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Up to 28 Days
- Number of Participants with Adverse Events (AEs)Time frame: Up to 48 months
- Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to 48 months
- Number of Participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 48 months
- Number of Participants with electrocardiogram (ECG) abnormalities and/or adverse events (AEs)Time frame: Up to 48 months
- Number of Participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to 48 months
- Number of Participants with physical exam abnormalities and/or adverse eventsTime frame: Up to 48 months
- Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance statusTime frame: Up to 48 months
Locations
68 sites in 7 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
UCLA Santa Monica Hematology Oncology
Santa Monica, California · Recruiting
Denver HealthONE Drug Development Unit
Denver, Colorado · Recruiting
Smilow Cancer Center at Yale New Haven Hospital
New Haven, Connecticut · Recruiting
Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
University of Florida, Davis Cancer Center
Gainesville, Florida · Recruiting
Florida Cancer Specialist
Lake Mary, Florida · Terminated
Florida Cancer Specialists & Research Institute Sarasota
Sarasota, Florida · Recruiting
University of Kansas Medical Center
Westwood, Kansas · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Trinity Health Ann Arbor Hospital
Ypsilanti, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Columbia University - Herbert Irving Comprehensive Cancer Center
New York, New York · Terminated
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Rochester Medical Center James P. Wilmot Cancer Center
Rochester, New York · Recruiting
Case Western
Cleveland, Ohio · Recruiting
Taylor Cancer Research Center
Maumee, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Terminated
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
NEXT Oncology - Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
University of Wisconsin Hospital
Madison, Wisconsin · Recruiting
Shanghai Pulmonary Hospital
Shanghai, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fudan University Shanghai Cancer Center
Xuhui District, Shanghai Municipality, China · Recruiting
Site FR33002
Bordeaux, France · Recruiting
Site FR33001
Lyon, France · Recruiting
Site FR33005
Lyon, France · Recruiting
Site FR33003
La Tronche, Grenobele, France · Recruiting
Site FR33004
Villejuif, Île-de-France Region, France · Recruiting
Osaka International Cancer Institute
Osaka, Japan · Recruiting
Aichi Cancer Center
Nagoya, Aichi-ken, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Shikoku Cancer Center
Matsuyama, Ehime, Japan · Recruiting
Kurume University Hospital
Kurume, Fukuoka, Japan · Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, Japan · Recruiting
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.